VectivBio_Logo_RGB_Color.png
VectivBio to Participate at the Bank of America 2022 Healthcare Conference
09 mai 2022 07h30 HE | VectivBio AG
BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications
21 avr. 2022 07h15 HE | VectivBio AG
BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Reports Full Year 2021 Financial Results and Provides Business Update
07 avr. 2022 07h15 HE | VectivBio AG
Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts
30 mars 2022 08h04 HE | VectivBio AG
Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial...
VectivBio_Logo_RGB_Color.png
VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition Conference
29 mars 2022 07h45 HE | VectivBio AG
-- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease -- -- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who...
VectivBio_Logo_RGB_Color.png
VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation
23 mars 2022 07h15 HE | VectivBio AG
-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI acute graft-versus-host disease (aGVHD)...
VectivBio_Logo_RGB_Color.png
VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference
08 févr. 2022 07h15 HE | VectivBio AG
BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Third Quarter 2021 Business Update
10 nov. 2021 08h30 HE | VectivBio AG
-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- -Expanded Rare Disease Pipeline with...
VectivBio_Logo_RGB_Color.png
VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference
04 nov. 2021 07h15 HE | VectivBio AG
BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease
20 oct. 2021 07h15 HE | VectivBio AG
-FDA clears IND application for apraglutide for acute graft-versus-host disease -- Dosing of first patient expected in 1Q 2022 -- Interim data anticipated in 2H 2022 -- FDA previously granted orphan...